FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312780237> ?p ?o ?g. }

• W4312780237 endingPage "7" @default.
• W4312780237 startingPage "1" @default.
• W4312780237 abstract "Etoricoxib is an oral selective cyclo-oxygenase-2 (COX-2) inhibitor with anti-inflammatory and antirheumatic properties belonging to the group of NSAIDs. Study Objective: The objective of this study was to investigate the bioequivalence study of Etoricoxib, Tricox® 120 mg film coated caplet manufactured by PT Guardian Pharmatama for PT Nulab Pharmaceutical Indonesia in comparison with Etoricoxib 120 mg, Arcoxia® film coated tablet manufactured by Frosst Iberica, S.A., Spain, registered and packed by PT Merck Sharp Dohme Pharma Tbk Pasuruan, East Java. Indonesia. Methods: The study was conducted using an open-label, randomized, single-dose, two-periods, two-treatment, crossover study under fasting for 10 hours with 7 (seven) days washed-out period between each period. A single oral dose of the test drug or reference drug was administered to 16 healthy male subjects. The number of subjects who finished the study was fourteen (14) healthy male subjects. Serial plasma samples were obtained over a 72 hours period. Plasma concentrations of the drug were determined by LC-MS/MS method. From the Etoricoxib concentration vs. time curves, the following pharmacokinetic parameters were obtained: AUC0-72h, AUC0-∞, and Cmax, while the statistical interval proposed was 80.00 - 125.00% for AUC0-72h and Cmax with 90% Confidence Interval (CI) with α = 5.00%. The estimation of Tmax and T1/2 in the bioequivalence study was based on a nonparametric statistical procedure on the original data using Wilcoxon Sign Test. Results: The main pharmacokinetic parameters of the test drug Tricox® (BN: T200909) compared to reference drug, Arcoxia® (BN: T015857) were calculated based on geometric mean ratio and 90% confidence interval (CI). The results for AUC0-72h and Cmax were 91.97% (87.50% – 96.66%) and 96.98% (88.41% – 106.36%) respectively, with intra-subject variability (%CV) were 13.56% for AUC0-72h and 7.28% for Cmax. Hence, the number of 14 (fourteen) subjects has adequate number for required power of study. Conclusion: The study demonstrated that the test drug Tricox® (BN: T200909) manufactured by PT Guardian Pharmatama for PT Nulab Pharmaceutical Indonesia bioequivalence in term of both rate and extent of absorption to the reference drug Arcoxia® (BN: T015857) manufactured by Frosst Iberica, S.A., Spain, registered and packed by PT Merck Sharp Dohme Pharma Tbk Pasuruan, East Java. Indonesia." @default.
• W4312780237 created "2023-01-05" @default.
• W4312780237 creator A5017630099 @default.
• W4312780237 date "2022-07-15" @default.
• W4312780237 modified "2023-09-25" @default.
• W4312780237 title "Bioequivalence Study of Etoricoxib 120 mg in Healthy Subjects" @default.
• W4312780237 doi "https://doi.org/10.23880/beba-16000172" @default.
• W4312780237 hasPublicationYear "2022" @default.
• W4312780237 type Work @default.
• W4312780237 citedByCount "0" @default.
• W4312780237 crossrefType "journal-article" @default.
• W4312780237 hasAuthorship W4312780237A5017630099 @default.
• W4312780237 hasBestOaLocation W43127802371 @default.
• W4312780237 hasConcept C112705442 @default.
• W4312780237 hasConcept C126322002 @default.
• W4312780237 hasConcept C12868164 @default.
• W4312780237 hasConcept C142724271 @default.
• W4312780237 hasConcept C181389837 @default.
• W4312780237 hasConcept C204787440 @default.
• W4312780237 hasConcept C206041023 @default.
• W4312780237 hasConcept C22979827 @default.
• W4312780237 hasConcept C27081682 @default.
• W4312780237 hasConcept C2776214540 @default.
• W4312780237 hasConcept C42404028 @default.
• W4312780237 hasConcept C44249647 @default.
• W4312780237 hasConcept C71924100 @default.
• W4312780237 hasConcept C87813604 @default.
• W4312780237 hasConcept C98274493 @default.
• W4312780237 hasConceptScore W4312780237C112705442 @default.
• W4312780237 hasConceptScore W4312780237C126322002 @default.
• W4312780237 hasConceptScore W4312780237C12868164 @default.
• W4312780237 hasConceptScore W4312780237C142724271 @default.
• W4312780237 hasConceptScore W4312780237C181389837 @default.
• W4312780237 hasConceptScore W4312780237C204787440 @default.
• W4312780237 hasConceptScore W4312780237C206041023 @default.
• W4312780237 hasConceptScore W4312780237C22979827 @default.
• W4312780237 hasConceptScore W4312780237C27081682 @default.
• W4312780237 hasConceptScore W4312780237C2776214540 @default.
• W4312780237 hasConceptScore W4312780237C42404028 @default.
• W4312780237 hasConceptScore W4312780237C44249647 @default.
• W4312780237 hasConceptScore W4312780237C71924100 @default.
• W4312780237 hasConceptScore W4312780237C87813604 @default.
• W4312780237 hasConceptScore W4312780237C98274493 @default.
• W4312780237 hasIssue "2" @default.
• W4312780237 hasLocation W43127802371 @default.
• W4312780237 hasOpenAccess W4312780237 @default.
• W4312780237 hasPrimaryLocation W43127802371 @default.
• W4312780237 hasRelatedWork W2349338867 @default.
• W4312780237 hasRelatedWork W2351830309 @default.
• W4312780237 hasRelatedWork W2353450705 @default.
• W4312780237 hasRelatedWork W2356698425 @default.
• W4312780237 hasRelatedWork W2357220270 @default.
• W4312780237 hasRelatedWork W2374069256 @default.
• W4312780237 hasRelatedWork W2387133671 @default.
• W4312780237 hasRelatedWork W2387566090 @default.
• W4312780237 hasRelatedWork W2392383498 @default.
• W4312780237 hasRelatedWork W48952282 @default.
• W4312780237 hasVolume "6" @default.
• W4312780237 isParatext "false" @default.
• W4312780237 isRetracted "false" @default.
• W4312780237 workType "article" @default.